Erratum: Hypoxia-cultured human adipose-derived mesenchymal stem cells are non-oncogenic and have enhanced viability, motility, and tropism to brain cancer (Cell Death and Disease (2014) 5 (e1567) DOI: 10.1038/cddis.2014.521);Hypoxia-cultured human adipose-derived mesenchymal stem cells are non-oncogenic and have enhanced viability, motility, and tropism to brain cancer

Cell Death and Disease

Volumn 5, Issue 12, 2014, Pages

  Feng, Y ^a,b   Zhu, M ^a,c   Dangelmajer, S ^a   Lee, Y M ^a   Wijesekera, O ^a   Castellanos, C X ^a   Denduluri, A ^a   Chaichana, K L ^a   Li, Q ^a   Zhang, H ^d   Levchenko, A ^e   Guerrero Cazares, H ^a   Quinones Hinojosa A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JIANGSU UNIVERSITY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e Yale University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; ENDOGLIN; THY 1 ANTIGEN; OXYGEN;

ADIPOSE DERIVED MESENCHYMAL STEM CELL; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CANCER; CELL DEATH; CELL DIFFERENTIATION; CELL MIGRATION; CELL MOTILITY; CELL VIABILITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCHYMAL STEM CELL; MIDDLE AGED; MOUSE; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; TROPISM; ADIPOSE TISSUE; BRAIN TUMOR; CELL CULTURE; CELL HYPOXIA; CELL LINE; CELL MOTION; CELL SURVIVAL; CYTOLOGY; MESENCHYMAL STROMA CELL; METABOLISM; PATHOPHYSIOLOGY;

ADIPOSE TISSUE; ADULT; AGED; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL HYPOXIA; CELL LINE; CELL MOVEMENT; CELL SURVIVAL; CELLS, CULTURED; FEMALE; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; OXYGEN; TROPISM;

EID: 84927950763     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.176     Document Type: Erratum

References (57)

1. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 2005; 7: 393-395.
2. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
3. Frenette PS, Pinho S, Lucas D, Scheiermann C. Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annu Rev Immunol 2013; 31: 285-316.
4. Sivanathan KN, Gronthos S, Rojas-Canales D, Thierry B, Coates PT. Interferon-gamma modification of mesenchymal stem cells: implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation. Stem Cell Rev 2014; 10: 351-375.
5. Ho IA, Toh HC, Ng WH, Teo YL, Guo CM, Hui KM et al. Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Stem Cells 2013; 31: 146-155.
6. Auffinger B, Morshed R, Tobias A, Cheng Y, Ahmed AU, Lesniak MS. Drug-loaded nanoparticle systems and adult stem cells: a potential marriage for the treatment of malignant glioma? Oncotarget 2013; 4: 378-396.
7. Tan J, Meng Y, Huang S, Wang P. Therapeutic gene products delivery by neuron stem cells. Curr Pharm Biotechnol 2012; 13: 2427-2431.
8. Gao Z, Zhang L, Hu J, Sun Y. Mesenchymal stem cells: a potential targeted-delivery vehicle for anti-cancer drug, loaded nanoparticles. Nanomedicine 2013; 9: 174-184.
9. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
10. Das R, Jahr H, van Osch GJ, Farrell E. The role of hypoxia in bone marrow-derived mesenchymal stem cells: considerations for regenerative medicine approaches. Tissue Eng Part B Rev 2010; 16: 159-168.
11. Ehtesham M, Stevenson CB, Thompson RC. Stem cell therapies for malignant glioma. Neurosurg Focus 2005; 19: E5.
12. Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, Raza SM, Pascual-Gallego M, Ibrahim A et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro Oncol 2014; 16: 113-122.
13. Chaichana KL, Pendleton C, Chambless L, Camara-Quintana J, Nathan JK, Hassam-Malani L et al. Multi-institutional validation of a preoperative scoring system which predicts survival for patients with glioblastoma. J Clin Neurosci 2013; 20: 1422-1426.
14. Chaichana KL, Chaichana KK, Olivi A, Weingart JD, Bennett R, Brem H et al. Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. J Neurosurg 2011; 114: 587-594.
15. McGirt MJ, Mukherjee D, Chaichana KL, Than KD, Weingart JD, Quiñones-Hinojosa A. Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery 2009; 65: 463-470.
16. Lee DH, Ahn Y, Kim SU, Wang KC, Cho BK, Phi JH et al. Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells. Clin Cancer Res 2009; 15: 4925-4934.
17. Koh CJ, Atala A. Tissue engineering, stem cells, and cloning: opportunities for regenerative medicine. J Am Soc Nephrol 2004; 15: 1113-1125.
18. Cogle CR, Guthrie SM, Sanders RC, Allen WL, Scott EW, Petersen BE. An overview of stem cell research and regulatory issues. Mayo Clin Proc 2003; 78: 993-1003.
19. Strioga M, Viswanathan S, Darinskas A, Slaby O, Michalek J. Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev 2012; 21: 2724-2752.
20. Pendleton C, Li Q, Chesler DA, Yuan K, Guerrero-Cazares H, Quiñones-Hinojosa A. Mesenchymal stem cells derived from adipose tissue vs bone marrow: in vitro comparison of their tropism towards gliomas. PLoS One 2013; 8: e58198.
21. Aust L, Devlin B, Foster SJ, Halvorsen YD, Hicok K, du Laney T et al. Yield of human adipose-derived adult stem cells from liposuction aspirates. Cytotherapy 2004; 6: 7-14.
22. Jurgens WFM, Oedayrajsingh-Varma M, Helder M, ZandiehDoulabi B, Schouten T, Kuik D et al. Effect of tissue-harvesting site on yield of stem cells derived from adipose tissue: implications for cell-based therapies. Cell Tissue Res 2008; 332: 415-426.
23. Griffiths S, Baraniak PR, Copland IB, Nerem RM, McDevitt TC. Human platelet lysate stimulates high-passage and senescent human multipotent mesenchymal stromal cell growth and rejuvenation in vitro. Cytotherapy 2013; 15: 1469-1483.
24. Tang H, Xiang Y, Jiang X, Ke Y, Xiao Z, Guo Y et al. Dual expression of hTERT and VEGF prolongs life span and enhances angiogenic ability of aged BMSCs. Biochem Biophys Res Commun 2013; 440: 502-508.
25. Madonna R, Taylor DA, Geng YJ, De Caterina R, Shelat H, Perin EC et al. Transplantation of mesenchymal cells rejuvenated by the overexpression of telomerase and myocardin promotes revascularization and tissue repair in a murine model of hindlimb ischemia. Circ Res 2013; 113: 902-914.
26. Otte A, Bucan V, Reimers K, Hass R. Mesenchymal stem cells maintain long-term in vitro stemness during explant culture. Tissue Eng Part C Methods 2013; 19: 937-948.
27. Beausejour C. Bone marrow-derived cells: the influence of aging and cellular senescence. Handb Exp Pharmacol 2007; 180: 67-88.
28. Fehrer C, Lepperdinger G. Mesenchymal stem cell aging. Exp Gerontol 2005; 40: 926-930.
29. Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbairn LJ, Bellantuono I. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells 2004; 22: 675-682.
30. Li Q, Wijesekera O, Salas SJ, Wang JY, Zhu M, Aprhys C et al. Mesenchymal stem cells from human fat engineered to secrete BMP4 are nononcogenic, suppress brain cancer, and prolong survival. Clin Cancer Res 2014; 20: 2375-2387.
31. Garzon-Muvdi T, Quiñones-Hinojosa A. Neural stem cell niches and homing: recruitment and integration into functional tissues. ILAR J 2009; 51: 3-23.
32. Haque N, Rahman MT, Abu Kasim NH, Alabsi AM. Hypoxic culture conditions as a solution for mesenchymal stem cell based regenerative therapy. Scientific World Journal 2013; 2013: 632972.
33. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009; 4: e4992.
34. Mishra PJ, Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 2008; 68: 4331-4339.
35. Moriyama H, Moriyama M, Isshi H, Ishihara S, Okura H, Ichinose A et al. Role of Notch signaling in the maintenance of human mesenchymal stem cells under hypoxic conditions. Stem Cells Dev 2014; 23: 2211-2224.
36. Chaichana KL, Cabrera-Aldana EE, Jusue-Torres I, Wijesekera O, Olivi A, Rahman M et al. When gross total resection of a glioblastoma is possible, how much resection should be achieved? World Neurosurg 2014: S1878-S8750.
37. Chaichana KL, McGirt MJ, Frazier J, Attenello F, Guerrero-Cazares H, Quiñones-Hinojosa A. Relationship of glioblastoma multiforme to the lateral ventricles predicts survival following tumor resection. J Neurooncol 2008; 89: 219-224.
38. Chaichana KL, Guerrero-Cazares H, Capilla-Gonzalez V, Zamora-Berridi G, Achanta P, Gonzalez-Perez O et al. Intra-operatively obtained human tissue: protocols and techniques for the study of neural stem cells. J Neurosci Methods 2009; 180: 116-125.
39. Garzon-Muvdi T, Schiapparelli P, ap Rhys C, Guerrero-Cazares H, Smith C, Kim DH et al. Regulation of brain tumor dispersal by NKCC1 through a novel role in focal adhesion regulation. PLoS Biol 2012; 10: e1001320.
40. Kosztowski T, Zaidi HA, Quiñones-Hinojosa A. Applications of neural and mesenchymal stem cells in the treatment of gliomas. Expert Rev Anticancer Ther 2009; 9: 597-612.
41. Quiñones-Hinojosa A, Chaichana K. The human subventricular zone: a source of new cells and a potential source of brain tumors. Exp Neurol 2007; 205: 313-324.
42. Momin EN, Mohyeldin A, Zaidi HA, Vela G, Quiñones-Hinojosa A. Mesenchymal stem cells: new approaches for the treatment of neurological diseases. Curr Stem Cell Res Ther 2010; 5: 326-344.
43. Aboody KS, Najbauer J, Metz MZ, D'Apuzzo M, Gutova M, Annala AJ et al. Neural stem cellmediated enzyme/prodrug therapy for glioma: preclinical studies. Sci Transl Med 2013; 5: 184ra59.
44. Bentivegna A, Miloso M, Riva G, Foudah D, Butta V, Dalpra L et al. DNA methylation changes during in vitro propagation of human mesenchymal stem cells: implications for their genomic stability? Stem Cells Int 2013; 2013: 192425.
45. Valorani MG, Montelatici E, Germani A, Biddle A, D'Alessandro D, Strollo R et al. Pre-culturing human adipose tissue mesenchymal stem cells under hypoxia increases their adipogenic and osteogenic differentiation potentials. Cell Prolif 2012; 45: 225-238.
46. Ni L, Liu X, Sochacki KR, Ebraheim M, Fahrenkopf M, Shi Q et al. Effects of hypoxia on differentiation from human placenta-derived mesenchymal stem cells to nucleus pulposus-like cells. Spine J 2014: S1529-S9430.
47. Sugrue T, Lowndes NF, Ceredig R. Hypoxia enhances the radio-resistance of mouse mesenchymal stromal cells. Stem Cells 2014; 32: 2188-2200.
48. Liu L, Yu Q, Lin J, Lai X, Cao W, Du K et al. Hypoxia-inducible factor-1α is essential for hypoxia-induced mesenchymal stem cell mobilization into the peripheral blood. Stem Cells Dev 2011; 20: 1961-1971.
49. Fotia C, Massa A, Boriani F, Baldini N, Granchi D. Hypoxia enhances proliferation and stemness of human adipose-derived mesenchymal stem cells. Cytotechnology 2014.
50. Wagegg M, Gaber T, Lohanatha FL, Hahne M, Strehl C, Fangradt M et al. Hypoxia promotes osteogenesis but suppresses adipogenesis of human mesenchymal stromal cells in a hypoxia-inducible factor-1 dependent manner. PLoS One 2012; 7: e46483.
51. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9: 157-173.
52. De Barros S, Dehez S, Arnaud E, Barreau C, Cazavet A, Perez G et al. Aging-related decrease of human ASC angiogenic potential is reversed by hypoxia preconditioning through ROS production. Mol Ther 2013; 21: 399-408.
53. Chang CP, Chio CC, Cheong CU, Chao CM, Cheng BC, Lin MT. Hypoxic preconditioning enhances the therapeutic potential of the secretome from cultured human mesenchymal stem cells in experimental traumatic brain injury. Clin Sci (Lond) 2013; 124: 165-176.
54. Hung SP, Ho JH, Shih YRV, Lo T, Lee OK. Hypoxia promotes proliferation and osteogenic differentiation potentials of human mesenchymal stem cells. J Orthop Res 2012; 30: 260-266.
55. Adesida AB, Mulet-Sierra A, Jomha NM. Hypoxia mediated isolation and expansion enhances the chondrogenic capacity of bone marrow mesenchymal stromal cells. Stem Cell Res Ther 2012; 3: 1-13.
56. Chaturvedi P, Gilkes DM, Wong CC, Luo W, Zhang H, Wei H et al. Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. J Clin Invest 2013; 123: 189-205.
57. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A et al. A multigene predictor of outcome in glioblastoma. Neuro Oncol 2010; 12: 49-57.